Related references
Note: Only part of the references are listed.Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder
Dmitry Y. Pushkar et al.
NEUROUROLOGY AND URODYNAMICS (2019)
Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients
Masaki Yoshida et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice
Christopher R. Chapple et al.
EUROPEAN UROLOGY (2017)
Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis
D. Sussman et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2017)
Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis
Wei Huang et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2015)
A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder
C. Park et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: Results of a real-life clinical study
Hironobu Akino et al.
INTERNATIONAL JOURNAL OF UROLOGY (2014)
Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013
Marcus J. Drake
NEUROUROLOGY AND URODYNAMICS (2014)
Cardiovascular effects of antimuscarinic agents in overactive bladder
Gian Marco Rosa et al.
EXPERT OPINION ON DRUG SAFETY (2013)
A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder
K. -S. Lee et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Long-Term Safety and Efficacy of Two Different Antimuscarinics, Imidafenacin and Solifenacin, for Treatment of Overactive Bladder: A Prospective Randomized Controlled Study
Teruhiko Yokoyama et al.
UROLOGIA INTERNATIONALIS (2013)
Imidafenacin, an Antimuscarinic Agent, Improves Nocturia and Reduces Nocturnal Urine Volume
Osamu Yokoyama et al.
UROLOGY (2013)
Pharmacological Effects of Imidafenacin (KRP-197/ONO-8025), a New Bladder Selective Anti-cholinergic Agent, in Rats
Fumiyoshi Kobayashi et al.
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH (2012)
Effects of Imidafenacin (KRP-197/ONO-8025), a New Anti-cholinergic Agent, on Muscarinic Acetylcholine Receptors
Fumiyoshi Kobayashi et al.
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH (2012)
Effect of Imidafenacin on Nocturia and Sleep Disorder in Patients with Overactive Bladder
Naoki Wada et al.
UROLOGIA INTERNATIONALIS (2012)
Effect of Bothersome Overactive Bladder Symptoms on Health-related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results From EpiLUTS
Ian Milsom et al.
UROLOGY (2012)
Selective Binding of Bladder Muscarinic Receptors in Relation to the Pharmacokinetics of a Novel Antimuscarinic Agent, Imidafenacin, to Treat Overactive Bladder
Shizuo Yamada et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats
Takanobu Yamazaki et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2011)
Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)
Masayoshi Zaitsu et al.
ADVANCES IN UROLOGY (2011)
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder
Yukio Homma et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder
Yukio Homma et al.
INTERNATIONAL JOURNAL OF UROLOGY (2008)
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms
Linda Brubaker et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2007)
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study
Debra E. Irwin et al.
EUROPEAN UROLOGY (2006)
Symptom assessment tool for overactive bladder syndrome- Overactive bladder symptom score
Yukio Homma et al.
UROLOGY (2006)
Nocturia: A new perspective on an old symptom
R Lundgren
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2004)
Pharmacological effects of KRP-197 on the human isolated urinary bladder
S Murakami et al.
UROLOGIA INTERNATIONALIS (2003)
The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society
P Abrams et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2002)
Prevalence and burden of overactive bladder in the United States
WF Stewart et al.
WORLD JOURNAL OF UROLOGY (2002)
Share Paper
